According to the report, Apple is working with a number of research institutions in the United States to develop applications to collect and organize genetic data of users. These apps will provide some iPhone users with the opportunity to help them with genetic testing. Among them, many people will be the first to conduct genetic testing. These new applications will be based on Apple's ResearchKit. This data integration platform collects information from user devices and packages the information for medical research. Hospitals and other researchers can connect to the ResearchKit platform to quickly access a large number of research samples. Apple's next step is to collect the user's genetic data. Researchers will save the data in ResearchKit's cloud computing platform, some of which will appear directly on the user's iPhone. A source also said that Apple hopes to announce new genetic applications at the World Developers Conference (WWDC) in June this year. Apple has not responded to this news. As the core technology of precision medicine , gene sequencing has gradually gained market attention. Not only overseas giants including Apple are accelerating the pace of genetic sequencing, but domestic authorities are also pushing for precise medical strategies. Earlier media reports, a few days ago, the Ministry of Science and Technology held the country's first expert meeting on precision medicine strategy, the meeting revealed that China's precision medical plan will be launched in the second half of 2015 or next year. According to the plan, by 2030, China's precision medical care will invest 60 billion yuan, of which the central government will pay 20 billion yuan, and the enterprise and local finance will support 40 billion yuan. According to the China Securities Network, Qin Huaijin, director of the Science and Technology Department of the National Health and Family Planning Commission, confirmed this news. "At present, the National Health and Family Planning Commission and the Ministry of Science and Technology are preparing for the precision medicine plan. After the improvement, it will be reported to the State Council, and it is expected to It is included in the national special project of the "13th Five-Year Plan" for scientific and technological development." Huatai Securities (601688) said that the innovation of precision medical care as a medical model is of great significance to improving the health of our nationals. The future investment is expected to increase, and the golden development period will be ushered in the development of genetic sequencing technology and national policies. Accurate treatment is the next emerging sunrise industry. It is recommended to actively focus on related investment opportunities such as gene sequencing, tumor diagnosis and personalized medicine. Corresponding to Daan Gene, Dean Diagnostics, Zixin Pharmaceutical, Qianshan Pharmaceutical, Xinyuan, North Lu Pharmaceutical, Hengrui Medicine and other stocks. Huatai Securities: Precision Medical Next Solar Industry Investment points: This article first puts forward the theme of precision medical investment concept. The article mainly explains what is precision medicine, why recommend precision medicine and explore corresponding investment opportunities at this time. What is precision medicine? Accurate medical treatment, also known as personalized medicine, refers to the combination of proteome, metabolome and other relevant internal environmental information based on personal genomic information, to design the best treatment plan for patients, in order to maximize the treatment effect and minimize side effects. A customized medical model. Therefore, compared with traditional medical treatment, precision medical treatment has the characteristics of pertinence, high efficiency and preventiveness, which will open a new era of medical treatment. The United States has actively promoted precision medicine and achieved certain results. Recently, Obama announced a precision medicine plan with a budget of $215 million in the State of the Union address. Why do we recommend precision medicine now? 1) The development of precision medicine in China is in the midst of a serious upward trend in medical expenditures, and the serious trend of domestic major disease mortality and neonatal disability rate is on the urgent need for precision treatment. The macro background; 2) the key to the development of precision medicine - genetic testing technology is welcoming the wind of policy and technology. First of all, the rapid development of gene sequencing technology at home and abroad has led to a significant drop in cost and opened up its huge commercial application space. Secondly, after a lapse of one year, the domestic notification of the pilot application of high-throughput gene sequencing prenatal screening and clinical application has cleared the obstacles for the development of industrialization, and the current gene sequencing industry has gradually become standardized. The future pilot is expected to be gradually released. Considering the rise of cancer diagnosis and personalized medicine, precision medicine is welcoming the development of the east. According to Illumina data, the global NGS (second generation gene sequencing) application market is expected to be 20 billion US dollars. Where are the investment opportunities for precision medicine? According to the above analysis, the innovation of precision medical care as a medical model is of great significance to improve the health of our nationals. The future investment is expected to increase, and the golden development period will be ushered in the development of gene sequencing technology and national policies. Taking non-invasive prenatal screening as an example, the number of newborns in China is about 16 million per year. According to the market penetration rate of 10%, 3,500 yuan/person, the market space is about 5.6 billion yuan/year. With the development of technology, the cost continues. The downside will further open up the market space. Assuming a downside of 1,500 yuan/person, and a penetration rate of 50%, the market space is expected to rise to 12 billion yuan/year. Considering the number of cancers of three to four million a year, the application of tumor diagnosis and personalized medicine is even greater. Therefore, precision treatment is the next emerging sunrise industry. It is recommended to actively pay attention to related investment opportunities such as gene sequencing, tumor diagnosis and personalized medicine. Corresponding to Daan Gene, Dean Diagnostics, Zixin Pharmaceutical, Qianshan Pharmaceutical, and New Open Source, Hokuriku Pharmaceutical, Hengrui Medicine and other stocks. Dean diagnosis: involved in tumor gene sequencing, marching into precision medicine Category: Company Research Institute: Haitong Securities Co., Ltd. Researcher: Yu Wenxin Date: 2015-04-09 event: On the evening of April 8, Dean diagnosed the announcement. The company received a notice from the National Health and Family Planning Commission on April 8. The company's wholly-owned subsidiary Hangzhou Dean Medical Testing Center Co., Ltd. achieved the first batch of tumor diagnosis and treatment projects. Flux gene sequencing technology clinical application pilot qualification. Comments: Involved in tumor gene sequencing, and entered the precision medicine. The meeting was notified by the Health Planning Commission to approve the use of high-throughput gene sequencing technology for cancer diagnosis and treatment. As the first batch of approved clinical trials of tumor fund sequencing, the company has demonstrated that the company has already possessed the soft power and hard power of applying gene sequencing technology to tumor diagnosis, marking the company's involvement in gene sequencing business and officially entering precision medicine. As the next generation of medical treatment technology, precision medicine has a great technical advantage over traditional methods of diagnosis and treatment. Compared with traditional methods of diagnosis and treatment, precision medicine has precision and convenience. On the one hand, genetic mutation can identify the mutation gene of cancer to quickly identify symptomatic drugs, eliminating the time for patients to try various treatment methods and improving the therapeutic effect; Aspect gene sequencing requires only the patient's blood and even saliva, without the need for traditional pathological sections, which can reduce the damage to the patient's body during the diagnosis process. It is foreseeable that the emergence of precision medical technology will significantly improve the diagnosis and treatment experience of cancer patients, and the development potential is great. The state has a strong support for precision medicine, and will invest 60 billion yuan by 2030. Following the announcement of the pre-production screening and diagnostic high-throughput sequencing pilot unit in January 2015, on March 11, 2015, the Ministry of Science and Technology held the first national expert meeting on precision medicine strategy and decided that the government will be in the field of precision medicine by 2030. Invest 60 billion yuan. The pilot unit for the publication of high-throughput gene sequencing for tumor diagnosis and treatment further demonstrates the government's determination to promote the development of precision medicine. Precision medicine is a natural extension of the company's existing channels and business, and can fully play synergies. First, the company can use the existing hospital channels and Ali Health's O2O channels to quickly spread cancer screening services nationwide; second, the sequencing of cancer treatment fills the gap in the company's business in this area, and enhances the company's third-party diagnosis. The overall strength; third, precision medicine can be combined with telemedicine , the company can collect samples for sequencing analysis, and then doctors to diagnose remotely. The introduction of precision medicine and the company's channels and existing business to form a complementary relationship, the company's overall strength is further enhanced. The company's layout in the field of third-party diagnostics has been fully rolled out, and multi-business collaboration has promoted high performance growth. Into the maternal and child diagnosis to expand the company's business areas and sales channels; to enter the third-party detection of O2O platform for the company to accumulate health data, to lay the foundation for the drug welfare management platform, chronic disease management platform, and expand the business channels; into the telemedicine The company further expanded its channels and enhanced the company's pathological diagnosis capabilities. With the advancement of precision medicine, the company's strength has further strengthened. It is expected that 15-17 years will be a period of rapid growth of the company's performance. Earnings forecast and investment suggestion: According to the shareholding of 235 million shares after the 55% equity of Bosheng Bio, we expect EPS of 0.97, 1.30, 1.69 yuan in 15-17 years, and consider the comparable company's 16-year average PE to be 121 times. 60 times PE in 16 years, corresponding to the target price of 117.00 yuan, buy rating. The main uncertainties: the progress of new business development is uncertain; the profitability of the new layout laboratory is uncertain. Zixin Pharmaceutical 2014 Annual Report Comments: Q4 Performance Increases Significantly Category: Company Research Institute: Northeast Securities Co., Ltd. Researcher: Liu Lin Date: 2015-02-25 Report summary: In the fourth quarter, both revenue and net profit increased significantly year-on-year. The company's total revenue last year was 776 million yuan, an increase of 63.42%. Among them, Q4's single-quarter revenue was 365 million yuan, an increase of 132.12%. Net profit was RMB 47 million, down 6.51% year-on-year; net profit after deduction was RMB 22 million, down 44.09% year-on-year. Among them, Q4's net profit in a single quarter was 95 million yuan, an increase of 438.30%. The significant increase in Q4 revenue and net profit was mainly attributable to the sales growth of the two subsidiaries of Prajna Pharmaceutical and Cao Dandan Pharmaceutical. The ginseng industry is steadily advancing. The company entered the ginseng industry in 2009. At present, it has developed more than 500 varieties of food, health products, cosmetics and so on. Dozens of ginseng products have been introduced to the market, including ginseng fruit and vegetable fermented beverages, ginseng drinks, jade red and red ginseng gelatin. Cake, fresh ginseng honey tablets, etc. Last year, the company's ginseng series products sales revenue of 424 million yuan, an increase of 185.71%; but the gross profit margin was only 37.8%, down 13.49%. The decrease in gross profit margin was mainly due to the rapid increase in the price of ginseng raw materials and the change in product sales structure. Last year, the company built three new stores in Changchun and Yanji, and has now distributed goods in about 300 circulation terminals in Changchun. This year, the company will promote the participation of breathing beverages, with Changchun as the center, advertising investment in the three provinces of Northeast China, and plans to build 5-10 model markets in the southern provinces, and gradually push to the national market. The gene sequencing industry is still an important factor in improving valuation. The second generation of high-throughput genetic sequencers is mainly operated by the subsidiary Zhongke Zixin. The second-generation gene sequencer technology is mainly in cooperation with the Beijing Genomics Institute of the Chinese Academy of Sciences. At present, the genetic sequencer is still in the stage of research and development. Investment suggestion: Without considering the increase, we expect the EPS of the company from 2015 to 2017 to be 0.09 yuan, 0.13 yuan and 0.17 yuan respectively. The current price-earnings ratio is high. However, the company's ginseng industry is still in a period of expansion, and there is greater flexibility in growth. The company is a listed company that is less pioneering in the genetic sequencing industry. Due to its high market attention, it can enjoy higher valuations and continue to increase Hold " rating. Risk warning: the risk of falling ginseng prices; genetic sequencers expand the risk of not reaching expectations. Snacks usually refer to the food eaten outside the time point of three meals a day. Under normal circumstances, in people's life, except that three meals a day are called dinner food, the rest are called snacks. Canned fruit is a healthy snack. AGOLYN wholesale all kinds of canned fruit, such as canned yellow peach, canned orange, etc Snacks,Canned Lychee,Canned Peaches,Canned Fruit Xi'an Gawen Biotechnology Co., Ltd , https://www.agolyn-bio.com